CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to evaluate efficacy and safety of delayed introduction
(up to 30 days post-transplantation in patients without signs of acute rejection that had
received an aIL-2 induction and MMF) of either cyclosporine or everolimus versus a 5-day
delay of cyclosporine in combination with MMF.